Definitive Healthcare (DH) to Post Quarterly Earnings on Monday

Definitive Healthcare (NASDAQ:DH) is expected to release its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect Definitive Healthcare to announce earnings of $0.04 per share and revenue of $55.4750 million for the quarter. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 5:00 PM ET.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $55.93 million for the quarter, compared to analysts’ expectations of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%. On average, analysts expect Definitive Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Definitive Healthcare Stock Performance

Definitive Healthcare stock opened at $0.68 on Monday. Definitive Healthcare has a 12-month low of $0.62 and a 12-month high of $4.70. The firm has a market capitalization of $72.00 million, a price-to-earnings ratio of -0.42, a P/E/G ratio of 11.01 and a beta of 1.35. The firm has a 50 day moving average of $0.80 and a 200 day moving average of $1.18. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.81.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of DH. Goldman Sachs Group Inc. grew its stake in Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after acquiring an additional 7,404,363 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Definitive Healthcare by 1.6% in the third quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock worth $8,417,000 after buying an additional 33,612 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Definitive Healthcare by 11.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock valued at $4,937,000 after buying an additional 127,055 shares during the last quarter. Bank of America Corp DE increased its stake in Definitive Healthcare by 23.7% in the 2nd quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock worth $3,001,000 after acquiring an additional 147,599 shares during the last quarter. Finally, Inspire Investing LLC boosted its position in shares of Definitive Healthcare by 505.7% during the 4th quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock valued at $2,006,000 after acquiring an additional 583,562 shares during the last quarter. Institutional investors own 98.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Bank of America restated an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research note on Monday, June 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Robert W. Baird set a $1.10 price target on Definitive Healthcare in a report on Friday, May 8th. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th. Finally, Zacks Research raised Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have given a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $2.47.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.